Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung

Jennifer M. Boland, Eugene D Kwon, Susan M. Harrington, Jason A. Wampfler, Hui Tang, Ping Yang, Marie Christine Aubry

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Background: Pulmonary squamous cell carcinoma has a poor prognosis, and new therapeutic targets are needed. The aberrant expression of the immunomodulatory proteins B7-H1 and B7-H3 by malignant cells may contribute to tumoral immune evasion. Data about the expression of these proteins by squamous cell carcinoma of the lung are limited. Materials and Methods: Immunohistochemistry for B7-H1 and B7-H3 was performed on 214 resected pulmonary squamous cell carcinoma specimens. Results: At the last follow-up, 171 of 214 (80%) of patients were deceased (median survival time, 3.76 years). Forty-two (19.6%) of 214 cases showed positivity with B7-H1, with a range of 5% to 60% of cells that stained positively. A total of 189 (88.3%) of 214 cases showed positivity with B7-H3, with a range of 5% to 80% of cells staining positively. By using multivariate analysis, no degree of B7-H1 or B7-H3 positivity was significantly associated with patient outcome. Conclusions: Although B7-H1 and B7-H3 are not of independent prognostic value, they are commonly expressed on a subset of tumor cells in pulmonary squamous cell carcinomas. Known interaction of the B7-H proteins with cytotoxic T-lymphocyte antigen-4 may make them attractive candidate biomarkers for response to immunomodulatory therapeutics, eg, ipilimumab, and warrants further study.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalClinical Lung Cancer
Volume14
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Squamous Cell Carcinoma
Lung
Neoplasms
CTLA-4 Antigen
Immune Evasion
Proteins
Multivariate Analysis
Biomarkers
Immunohistochemistry
Staining and Labeling
Survival
Therapeutics

Keywords

  • B7-H1
  • B7-H3
  • Lung cancer
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Boland, J. M., Kwon, E. D., Harrington, S. M., Wampfler, J. A., Tang, H., Yang, P., & Aubry, M. C. (2013). Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clinical Lung Cancer, 14(2), 157-163. https://doi.org/10.1016/j.cllc.2012.05.006

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. / Boland, Jennifer M.; Kwon, Eugene D; Harrington, Susan M.; Wampfler, Jason A.; Tang, Hui; Yang, Ping; Aubry, Marie Christine.

In: Clinical Lung Cancer, Vol. 14, No. 2, 03.2013, p. 157-163.

Research output: Contribution to journalArticle

Boland, JM, Kwon, ED, Harrington, SM, Wampfler, JA, Tang, H, Yang, P & Aubry, MC 2013, 'Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung', Clinical Lung Cancer, vol. 14, no. 2, pp. 157-163. https://doi.org/10.1016/j.cllc.2012.05.006
Boland, Jennifer M. ; Kwon, Eugene D ; Harrington, Susan M. ; Wampfler, Jason A. ; Tang, Hui ; Yang, Ping ; Aubry, Marie Christine. / Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. In: Clinical Lung Cancer. 2013 ; Vol. 14, No. 2. pp. 157-163.
@article{fc7f4bb39ea7499fbcea7ab5fa1b8e87,
title = "Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung",
abstract = "Background: Pulmonary squamous cell carcinoma has a poor prognosis, and new therapeutic targets are needed. The aberrant expression of the immunomodulatory proteins B7-H1 and B7-H3 by malignant cells may contribute to tumoral immune evasion. Data about the expression of these proteins by squamous cell carcinoma of the lung are limited. Materials and Methods: Immunohistochemistry for B7-H1 and B7-H3 was performed on 214 resected pulmonary squamous cell carcinoma specimens. Results: At the last follow-up, 171 of 214 (80{\%}) of patients were deceased (median survival time, 3.76 years). Forty-two (19.6{\%}) of 214 cases showed positivity with B7-H1, with a range of 5{\%} to 60{\%} of cells that stained positively. A total of 189 (88.3{\%}) of 214 cases showed positivity with B7-H3, with a range of 5{\%} to 80{\%} of cells staining positively. By using multivariate analysis, no degree of B7-H1 or B7-H3 positivity was significantly associated with patient outcome. Conclusions: Although B7-H1 and B7-H3 are not of independent prognostic value, they are commonly expressed on a subset of tumor cells in pulmonary squamous cell carcinomas. Known interaction of the B7-H proteins with cytotoxic T-lymphocyte antigen-4 may make them attractive candidate biomarkers for response to immunomodulatory therapeutics, eg, ipilimumab, and warrants further study.",
keywords = "B7-H1, B7-H3, Lung cancer, Squamous cell carcinoma",
author = "Boland, {Jennifer M.} and Kwon, {Eugene D} and Harrington, {Susan M.} and Wampfler, {Jason A.} and Hui Tang and Ping Yang and Aubry, {Marie Christine}",
year = "2013",
month = "3",
doi = "10.1016/j.cllc.2012.05.006",
language = "English (US)",
volume = "14",
pages = "157--163",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung

AU - Boland, Jennifer M.

AU - Kwon, Eugene D

AU - Harrington, Susan M.

AU - Wampfler, Jason A.

AU - Tang, Hui

AU - Yang, Ping

AU - Aubry, Marie Christine

PY - 2013/3

Y1 - 2013/3

N2 - Background: Pulmonary squamous cell carcinoma has a poor prognosis, and new therapeutic targets are needed. The aberrant expression of the immunomodulatory proteins B7-H1 and B7-H3 by malignant cells may contribute to tumoral immune evasion. Data about the expression of these proteins by squamous cell carcinoma of the lung are limited. Materials and Methods: Immunohistochemistry for B7-H1 and B7-H3 was performed on 214 resected pulmonary squamous cell carcinoma specimens. Results: At the last follow-up, 171 of 214 (80%) of patients were deceased (median survival time, 3.76 years). Forty-two (19.6%) of 214 cases showed positivity with B7-H1, with a range of 5% to 60% of cells that stained positively. A total of 189 (88.3%) of 214 cases showed positivity with B7-H3, with a range of 5% to 80% of cells staining positively. By using multivariate analysis, no degree of B7-H1 or B7-H3 positivity was significantly associated with patient outcome. Conclusions: Although B7-H1 and B7-H3 are not of independent prognostic value, they are commonly expressed on a subset of tumor cells in pulmonary squamous cell carcinomas. Known interaction of the B7-H proteins with cytotoxic T-lymphocyte antigen-4 may make them attractive candidate biomarkers for response to immunomodulatory therapeutics, eg, ipilimumab, and warrants further study.

AB - Background: Pulmonary squamous cell carcinoma has a poor prognosis, and new therapeutic targets are needed. The aberrant expression of the immunomodulatory proteins B7-H1 and B7-H3 by malignant cells may contribute to tumoral immune evasion. Data about the expression of these proteins by squamous cell carcinoma of the lung are limited. Materials and Methods: Immunohistochemistry for B7-H1 and B7-H3 was performed on 214 resected pulmonary squamous cell carcinoma specimens. Results: At the last follow-up, 171 of 214 (80%) of patients were deceased (median survival time, 3.76 years). Forty-two (19.6%) of 214 cases showed positivity with B7-H1, with a range of 5% to 60% of cells that stained positively. A total of 189 (88.3%) of 214 cases showed positivity with B7-H3, with a range of 5% to 80% of cells staining positively. By using multivariate analysis, no degree of B7-H1 or B7-H3 positivity was significantly associated with patient outcome. Conclusions: Although B7-H1 and B7-H3 are not of independent prognostic value, they are commonly expressed on a subset of tumor cells in pulmonary squamous cell carcinomas. Known interaction of the B7-H proteins with cytotoxic T-lymphocyte antigen-4 may make them attractive candidate biomarkers for response to immunomodulatory therapeutics, eg, ipilimumab, and warrants further study.

KW - B7-H1

KW - B7-H3

KW - Lung cancer

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84875238628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875238628&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2012.05.006

DO - 10.1016/j.cllc.2012.05.006

M3 - Article

VL - 14

SP - 157

EP - 163

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -